Pregabalin Sandoz
pregabalin
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Pregabalin Sandoz. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pregabalin Sandoz.
For practical information about using Pregabalin Sandoz, patients should read the package leaflet or contact their doctor or pharmacist.
-
List item
Pregabalin Sandoz : EPAR - Summary for the public (PDF/121.37 KB)
First published: 16/07/2015
Last updated: 16/07/2015
EMA/277953/2015 -
-
List item
Pregabalin Sandoz : EPAR - Risk-management-plan summary (PDF/36.26 KB)
First published: 16/07/2015
Last updated: 27/08/2020
Authorisation details
Product details | |
---|---|
Name |
Pregabalin Sandoz
|
Agency product number |
EMEA/H/C/004010
|
Active substance |
pregabalin
|
International non-proprietary name (INN) or common name |
pregabalin
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
N03AX16
|
Generic |
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines. |
Publication details | |
---|---|
Marketing-authorisation holder |
Sandoz GmbH
|
Revision |
16
|
Date of issue of marketing authorisation valid throughout the European Union |
19/06/2015
|
Contact address |
Biochemiestr. 10
6250 Kundl Austria |
Product information
13/06/2023 Pregabalin Sandoz - EMEA/H/C/004010 - IB/0031
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antiepileptics
Therapeutic indication
Neuropathic pain
Pregabalin Sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults.
Epilepsy
Pregabalin Sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
Generalised Anxiety Disorder
Pregabalin Sandoz is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.